BioAge Labs to Present at Jefferies Global Healthcare Conference in London
Rhea-AI Summary
BioAge Labs (NASDAQ: BIOA) will present at the Jefferies Global Healthcare Conference in London on November 17–20, 2025. The company said CEO Kristen Fortney, PhD, and CFO Dov Goldstein, MD, will join a fireside chat on Monday, November 17 from 7:30–7:55 AM ET (12:30–1:00 PM GMT) and will hold one-on-one meetings.
Investors can watch a live webcast by registering via the company link and access replays in the investor section at https://ir.bioagelabs.com/; replays will be archived for 30 days after the presentations.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BIOA declined 2.81%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025.
Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 - 7:55 AM ET (12:30 - 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity and cardiovascular risk factors. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When will BioAge Labs (BIOA) present at the Jefferies Global Healthcare Conference in London?
What time is the BioAge (BIOA) fireside chat on November 17, 2025?
Who will represent BioAge Labs (BIOA) at the Jefferies conference on November 17, 2025?
How can investors watch the BioAge (BIOA) presentation webcast on November 17, 2025?
Where will BioAge (BIOA) replay recordings be available and for how long after November 17, 2025?
